SNBP showed net income of $1,073,550 for the three months ended November 30, 2009, as compared to a net loss of $1,045,239 for the three months ended November 30, 2008, and a net income of $1,310,717 for the six months ended November 30, 2009, as compared to a net loss of $897,376 for the six months ended November 30, 2008.
Their sales increased 120% to $2,137,471 for the three months ended November 30, 2009, from $971,173 for the three months ended November 30, 2008. Gross margin increased 182% to $1,720,308 (80% of sales) for the three months ended November 30, 2009, from $610,752 (63% of sales) for the three months ended November 30, 2008.
For the six months ended November 30, 2009 increased 80% to $3,431,235 from $1,902,376 for the six months ended November 30, 2008. An increase in gross margin of 119% to $2,683,231 for the six months ended November 30, 2009, from $1,223,180 (64% of sales) for the six months ended November 30, 2008.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
